What is the appropriate workup and treatment for elevated parathyroid hormone with normal serum calcium?

Elevated Parathyroid Hormone with Normal Calcium

The first priority is to systematically exclude all secondary causes of hyperparathyroidism before considering normocalcemic primary hyperparathyroidism (NPHPT), with vitamin D deficiency and inadequate calcium intake being the most common reversible causes that must be corrected and reassessed over at least 6 months 1, 2.

Initial Diagnostic Workup

Essential Laboratory Measurements

• Measure ionized calcium (not just total calcium) to confirm true normocalcemia, as total calcium can be misleading in borderline cases 2
• Check 25-hydroxyvitamin D levels - must be >30 ng/mL (>75 nmol/L) and maintained at this level for at least 6 months before accepting NPHPT diagnosis 1, 2
• Assess renal function with estimated glomerular filtration rate (eGFR) - chronic kidney disease is a common cause of secondary hyperparathyroidism 3
• Measure serum phosphate - low phosphate suggests possible phosphate wasting disorders 4
• Obtain 24-hour urinary calcium and calculate fractional excretion of calcium to exclude familial hypocalciuric hypercalcemia 1

Critical Secondary Causes to Exclude

Vitamin D insufficiency is the most frequent culprit. Supplement with cholecalciferol or ergocalciferol to achieve 25-OH vitamin D >30 ng/mL, then reassess PTH after 6+ months of adequate levels 1, 2.

Inadequate calcium intake is often overlooked. Evaluate dietary calcium using a standardized questionnaire 2. If intake is insufficient (<1000-1200 mg/day), trial calcium supplementation 600 mg twice daily for 2-3 weeks and recheck PTH 5. In one series, all patients with secondary hyperparathyroidism from low calcium intake normalized their PTH within 18 days of supplementation 5.

Chronic kidney disease (eGFR <60 mL/min/1.73 m²) causes secondary hyperparathyroidism through phosphate retention and impaired vitamin D activation 3. For CKD Stage 3, treatment with active vitamin D (calcitriol 0.25-0.5 μg daily or alfacalcidol 0.25-0.5 μg daily) is indicated when PTH exceeds target ranges 3.

Malabsorption conditions including bariatric surgery, celiac disease, or inflammatory bowel disease impair calcium absorption and require investigation 6, 2.

Medications such as loop diuretics, bisphosphonates, or denosumab can elevate PTH and should be reviewed.

Diagnostic Algorithm

1. Confirm persistent elevation: Repeat PTH and calcium (total and ionized) at least twice, separated by weeks to months 7, 8

2. Exclude secondary causes systematically:

   • Vitamin D <30 ng/mL → supplement and recheck in 6+ months
   • Low dietary calcium → supplement 1200 mg/day and recheck in 2-4 weeks
   • eGFR <60 → manage as CKD-related secondary hyperparathyroidism
   • Malabsorption history → evaluate and treat underlying condition

3. Consider oral calcium loading test if diagnosis remains unclear after excluding secondary causes. In NPHPT, calcium loading produces hypercalcemia with non-suppressed PTH, whereas secondary hyperparathyroidism shows appropriate PTH suppression 1, 2.

Management of Confirmed NPHPT

When to Consider Parathyroidectomy

Surgery should be considered for symptomatic patients with:

• Osteoporosis (T-score ≤-2.5) or fragility fractures
• Nephrolithiasis or nephrocalcinosis
• eGFR <60 mL/min/1.73 m² attributable to hyperparathyroidism
• Hypercalciuria (>400 mg/24 hours) 7, 8, 9

Important surgical considerations: NPHPT patients have higher rates of multigland disease and smaller adenomas compared to hypercalcemic primary hyperparathyroidism, making preoperative localization more challenging and bilateral neck exploration more likely 9. Intraoperative PTH may fall <50% less frequently than in hypercalcemic disease 9. Surgery should be performed by experienced parathyroid surgeons capable of four-gland exploration.

Postoperative outcomes: Bone mineral density improves significantly after successful parathyroidectomy, though renal outcomes are less certain and recurrence rates may be higher than in hypercalcemic disease 7, 9, 10.

Medical Management

For patients who are not surgical candidates or decline surgery:

• Alendronate has shown efficacy in improving bone density in NPHPT patients 9
• Continue calcium and vitamin D supplementation to maintain optimal levels
• Monitor bone density every 1-2 years
• Screen for kidney stones with renal imaging if not already performed

Common Pitfalls to Avoid

Do not diagnose NPHPT prematurely. The diagnosis requires excluding all secondary causes with certainty, which takes time - particularly ensuring vitamin D adequacy for 6+ months 1, 2.

Do not assume normal total calcium equals normal ionized calcium. Always measure ionized calcium in borderline cases 2.

Do not overlook inadequate calcium intake, especially in elderly patients, those avoiding dairy, or post-bariatric surgery patients. A simple calcium supplementation trial can be diagnostic and therapeutic 5.

Recognize PTH assay variability. Different PTH assay generations measure fragments differently, which can affect interpretation, though this matters less for diagnosis than for monitoring treatment 11.

Be aware that NPHPT may not progress to hypercalcemia - its natural history is variable and not all patients develop classic hypercalcemic disease 12.